Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Fineline Cube Jan 12, 2026
Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Fineline Cube Jan 12, 2026
Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Fineline Cube Jan 12, 2026
Company Deals

Shanghai OPM Biosciences Plans Acqusition of PharmaLegacy Labs for RMB 1.45 Billion

Fineline Cube Jun 6, 2025

Shanghai OPM Biosciences Co., Ltd (SHA: 688293), a China-based cell culture-focused Contract Development and Manufacturing...

Company Drug

Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis

Fineline Cube Jun 6, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...

Policy / Regulatory

NHSA Strengthens Pharmaceutical Pricing and Procurement Credit Evaluation Mechanism

Fineline Cube Jun 6, 2025

The National Healthcare Security Administration (NHSA) issued a notification this week to refine its credit...

Policy / Regulatory

China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations

Fineline Cube Jun 6, 2025

China’s National Medical Products Administration (NMPA), Ministry of Finance (MoF), and State Administration for Market...

Policy / Regulatory

China’s National Health Commission Mandates Labor Pain Management Services Expansion

Fineline Cube Jun 6, 2025

China’s National Health Commission (NHC) issued a notification mandating the comprehensive promotion of labor pain...

Company Deals

Intragrand Pharma Licenses Lenamilast to Transpire Bio for Global Development

Fineline Cube Jun 6, 2025

China-based Suzhou Intragrand Pharma has entered into a licensing agreement with U.S.-headquartered Transpire Bio Inc....

Company Deals

Consun Pharma Partners with DP Technology to Accelerate AI-Driven Kidney Disease Drug R&D

Fineline Cube Jun 6, 2025

China-based Consun Pharmaceutical Group Ltd (HKG: 1681) announced a strategic partnership with compatriot firm DP...

Company Drug

Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE

Fineline Cube Jun 5, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion...

Company Drug

BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes

Fineline Cube Jun 5, 2025

US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received an indication extension...

Company Deals

Shanghai Pharma Partners with Chugai Pharma China to Enhance Bone Health Products

Fineline Cube Jun 5, 2025

China’s Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607; SPH) has established a partnership...

Company Deals

Genrix Bio Partners with Cullinan Therapeutics for GR1803 License

Fineline Cube Jun 5, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...

Company Drug

AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China

Fineline Cube Jun 5, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) received approval from China’s National Medical Products Administration...

Company Drug

Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication

Fineline Cube Jun 5, 2025

China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...

Company Drug

Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval

Fineline Cube Jun 5, 2025

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has...

Company Drug

Wantai Biopharm’s Cecolin 9 HPV Vaccine Approved by China’s NMPA

Fineline Cube Jun 5, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its 9-valent human...

Company Drug

Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials

Fineline Cube Jun 5, 2025

Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...

Company Drug

NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination

Fineline Cube Jun 5, 2025

Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013)...

Company Deals

SciBrunch Therapeutics Secures RMB 200 Million in Angel Financing Round

Fineline Cube Jun 5, 2025

Shanghai-based SciBrunch Therapeutics, a developer of small molecule anti-tumor drugs, has reportedly secured over RMB...

Company Drug

JW Therapeutics’ Carteyva Approved by Macau Health Bureau

Fineline Cube Jun 5, 2025

JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...

Company Deals

Sichuan Kelun-Biotech Raises $250M in Hong Kong’s Largest Follow-On Offering

Fineline Cube Jun 5, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the successful placement of 5,918,000 new...

Posts pagination

1 … 90 91 92 … 607

Recent updates

  • Biocytogen Licenses ADC Programs to Acepodia in Option Deal
  • Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO
  • Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform
  • Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study
  • Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.